For Accredited Investors Only · Confidential · Not an Offer or Solicitation
Team & Advisers

Experience Across Science, Operations & Transactions

The general-partner team combines biotech, clinical, operating and healthcare transaction experience relevant to Aether's strategy. Detailed CVs and transaction roles are available for investor diligence.

EP

Elizabeth Parrish, MBA

Science & Asset Strategy

BioViva founder; regenerative-medicine strategy, asset development and global relationships.

TD

Tucson Dunn

M&A, Integration & Operations

Healthcare M&A, operating integration and clinical asset development.

ED

Eugene Durenard, PhD

Fund Structure & Investment Strategy

Fund architecture, capital allocation and global biotechnology investing.

JD

Jordan Dawson, PharmD

Clinical Strategy & Portfolio Development

Healthcare opportunity sourcing, clinical/translational diligence, evidence & RWE strategy, and portfolio oversight.

DP

Daniel Passarelli

Capital Formation & Investor Relations

Capital-markets strategy, investor relationships and financing coordination.

Advisers / Asset Leadership

Scientific & Clinical Advisers

DC

Diana Castro, MD

Clinical Adviser
SJ

Sheldon Jordan, MD, FAAN

Neurology Adviser
BA

Bill Andrews, PhD

Science Adviser
Request Access to the Data Room

Important information. Confidential discussion material for accredited investors only; not an offer or solicitation. Team and adviser roles are described for context and are subject to definitive documentation. Nothing here is a performance representation, promise or guarantee.